<DOC>
	<DOCNO>NCT01918332</DOCNO>
	<brief_summary>This study aim evaluate efficacy safety coadministration valsartan ( Diovan® ) 160mg rosuvastatin ( Crestor® ) 20mg comparison component administer alone patient hypertension hyperlipidemia .</brief_summary>
	<brief_title>Efficacy Safety Valsartan 160mg Rosuvastatin 20mg Patients With Hypertension Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Patient age 2080 year hypertension hyperlipidemia 2 . Patient Hypertension 3 . Patient Hyperlipidemia accord NCEPATP III guideline ( 2004 ) 4 . Patient sign Informed Consent Form receive explanation purpose , method , effect study 1 . If blood pressure fast serum lipid level measure screen Visit 2 ( 0 week ) satisfy follow criterion 1 ) sitSBP≥180mmHg sitDBP≥110mmHg ( For high risk group , sitSBP≥ 160mmHg sitDBP ≥100mmHg ) 2 ) LDLC &gt; 250mg/dL , TG≥ 400mg/dL 2 . If sitSBP difference right leave arm &gt; 20mmHg sitDBP difference right leave arm &gt; 10mmHg screen 3 . When blood pressure repeatedly measure select arm screening , sitSBP difference ≥ 20mmHg sitDBP difference ≥10mmHg 4 . Patient orthostatic hypotension accompany symptom screen ( decrease sitDBP ≥10mmHg decrease sitSBP ≥ 20mmHg )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>